The MYCNOS gene is indeed a notable gene in the context of neuroblastoma and is part of a larger regulatory network involving oncogenes. Here is an extended view of the MYCNOS gene that addresses your requests:

1. **Associated Genes and Interactions**:
   - **MYCN**: As an antisense RNA, MYCNOS regulates MYCN directly. The stability and activity of MYCN are critical in neuroblastoma.
   - **GSK3B (Glycogen Synthase Kinase 3 Beta)**: MYCNOS inhibits GSK3B activity, leading to reduced phosphorylation of MYCN, which is important for its stability.
   - **RB (Retinoblastoma protein)**: MYCNOS might be indirectly associated through the effects of MYCN on cell cycle regulation and proliferation.
   - **Other genes of interest**: While not directly stated in the summaries, genes that are downstream of MYCN signaling, such as those involved in cell cycle regulation, apoptosis, and differentiation, might also be implicated. This includes various Ccnd and Cmyc family members.

2. **Aging and Age-Related Diseases**:
   - There is limited direct information correlating MYCNOS with aging or specific age-related diseases. However, aberrant expressions of MYCN and MYCNOS have been associated with neuroblastoma, particularly in pediatric populations. The dysregulation of such oncogenes may suggest a potential role in tumor suppression mechanisms that could impact age-related oncogenesis, particularly in the context of cancer development as individuals age. Another indirect association is that there may be implications in neurodegenerative diseases if neuroblastoma-associated pathways influence cellular mechanisms related to aging.

3. **Drug Interactions**:
   - Specific drug classes known to interact with the pathways involving MYCNOS include:
     - **GSK3 Inhibitors**: Since MYCNOS regulates GSK3B activity, inhibitors of GSK3 may affect the pathway that MYCNOS is part of. Examples include lithium and other experimental GSK3 inhibitors.
     - **Therapeutics for Neuroblastoma**: Agents used in neuroblastoma treatment, such as topoisomerase inhibitors (e.g., doxorubicin) or monoclonal antibodies targeting neuroblastoma markers, can indirectly affect the gene expression and regulation downstream of MYCN/MYCNOS.

4. **Pathways and Biological Processes**:
   - **Wnt Signaling Pathway**: As GSK3B is a critical regulator in this pathway, MYCNOS’s inhibition of GSK3B may affect Wnt signaling, which plays important roles in cell proliferation, differentiation, and survival.
   - **Cell Cycle Regulation**: MYCN activation promotes cell cycle progression, and MYCNOS may enhance this through stabilizing MYCN and influencing cell proliferation.
   - **Apoptosis Regulation**: By promoting cell survival and inhibiting apoptosis through MYCN stabilization, MYCNOS contributes to oncogenesis, particularly in the context of neuroblastoma.
   - **Transcriptional Regulation**: MYCNOS may possess enhancer-like properties that modulate the transcriptional activity of MYCN by acting as a functional RNA.

Overall, MYCNOS is identified as an essential regulatory element in the oncogenic pathway involving MYCN, with potential implications for therapeutic strategies targeting neuroblastoma and other cancers. Further research might elucidate its broader roles, especially concerning aging and treatment responses.